CME Group (CME) opened 2026 with Q1 revenue of US$1.9b and basic EPS of US$3.25, setting the tone for another data rich update for shareholders. The company has seen quarterly revenue move from US$1.6b in Q1 2025 to US$1.9b in Q1 2026, while basic EPS has shifted from US$2.63 to US$3.25 over the same period, against a backdrop of trailing 12 month earnings growth of 18.5%. For investors, the combination of higher trailing net margins and these headline figures puts the focus firmly on how durable CME Group's profitability profile looks from here.

See our full analysis for CME Group.

With the latest earnings picture in place, the next step is to see how these numbers line up with the widely followed narratives about CME Group, and where those stories might need to be updated.

Margins stay high at 62.9%

• Over the last 12 months, CME Group generated about US$6.7b in revenue and US$4.2b in net income, which works out to a 62.9% net margin compared with 57.1% the prior year.
• Consensus narrative points to strong demand for risk management and growing international volumes as long term drivers, and the current 62.9% margin and trailing 18.5% earnings growth give that bullish view some support, although:
  • Forecast earnings growth of about 3.3% per year is much lower than the recent 18.5% pace, so the current margin level is not assumed to keep lifting profits at the same rate.
  • Analysts also expect profit margins to move from 61.8% to 55.2% over three years, which contrasts with the recent margin expansion and adds some caution to the bullish case.

Bulls argue that CME's mix of global risk hedging demand, retail participation and data revenue can keep margins attractive over time even if growth settles at more modest levels, and this earnings print gives a clear look at why that argument has gained traction 🐂 CME Group Bull Case

P/E of 24.4x versus peers

• CME Group trades on a 24.4x P/E, which sits below both the US Capital Markets industry average of 41.7x and a peer average of 29.4x.
• What stands out in the bullish narrative is the idea that durable earnings and high margins could justify a premium, yet:
  • The current P/E of 24.4x is below the analyst price target implication of about 26.2x using the current share price of US$285.78 and the allowed target of US$309.87, suggesting the market is not paying up as much as that view might imply.
  • At the same time, forecasts of modest 3.3% annual earnings growth contrast with the stronger 12.5% five year average growth, which helps explain why the current multiple is below industry and peer levels despite the quality of recent results.

DCF fair value and dividend coverage

• The shares trade at US$285.78 compared with a DCF fair value of about US$245.14, while the 3.97% dividend yield is flagged as not well covered by free cash flow.
• Skeptics focus on this gap between price and cash flow value, and the numbers here give that bearish angle some footing, because:
  • The current price is roughly US$40 above the DCF fair value, which lines up with the concern that the market is valuing CME ahead of the discounted cash flow estimate.
  • With forecast earnings growth of 3.3% per year and revenue growth of 4.9% per year, the combination of modest forward growth and weaker free cash flow cover for a 3.97% dividend is exactly the type of setup bearish investors point to as a risk to long term returns.

Critics warn that a share price above DCF fair value and a dividend not fully backed by free cash flow leave less room for error if growth stays at the forecast pace 🐻 CME Group Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CME Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards on the table, it is worth checking the underlying numbers yourself and deciding how comfortable you are with CME Group's setup, then weigh those signals against the 2 key rewards and 2 important warning signs

See What Else Is Out There

CME Group faces a share price above its DCF fair value, modest forecast earnings growth of 3.3% per year, and a 3.97% dividend flagged as not well covered by free cash flow.

If you are uneasy about paying a premium for modest growth and a dividend with weaker cash flow backing, compare that setup with companies in the 13 dividend fortresses

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.